Glutaminergic Transmission in Autism : Molecular Imaging Exploration
Overview
- Phase
- Phase 1
- Intervention
- Biological samples
- Conditions
- Autism
- Sponsor
- University Hospital, Tours
- Enrollment
- 27
- Locations
- 1
- Primary Endpoint
- cerebral glutaminergic activity assessed by binding potential of [18F]FPEB
- Status
- Completed
- Last Updated
- 4 months ago
Overview
Brief Summary
Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers
Investigators
Eligibility Criteria
Inclusion Criteria
- •Between 18 years-old and 45 years-old
- •Informed, written consent obtained from patient or his representant
- •Subject with an affiliation to French social security
- •For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders) following DSM-IV or DSM-5 criteria with recommended tools (ADI-R and/or ADOS)
- •For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1
Exclusion Criteria
- •Contraindications to MRI
- •Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months
- •Any unstable or uncontrolled disease, clinically significant
- •Participation to an other experimental protocol with drug or irradiant exam
- •Person under exclusion period because of previous participation to an other experimental protocol
- •Person under temporary guardianship
- •Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and changing durably glutaminergic transmission directly or undirectly
- •For healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (MINI DSM-IV)
Arms & Interventions
Healthy subjects
\[18F\]FPEB PET imaging MRI Biological samples
Intervention: Biological samples
autistic patients
\[18F\]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
Intervention: [18F]FPEB PET imaging
autistic patients
\[18F\]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
Intervention: Biological samples
autistic patients
\[18F\]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
Intervention: MRI
FXS patients
\[18F\]FPEB PET imaging MRI Biological samples
Intervention: [18F]FPEB PET imaging
FXS patients
\[18F\]FPEB PET imaging MRI Biological samples
Intervention: Biological samples
FXS patients
\[18F\]FPEB PET imaging MRI Biological samples
Intervention: MRI
Healthy subjects
\[18F\]FPEB PET imaging MRI Biological samples
Intervention: [18F]FPEB PET imaging
Healthy subjects
\[18F\]FPEB PET imaging MRI Biological samples
Intervention: MRI
Outcomes
Primary Outcomes
cerebral glutaminergic activity assessed by binding potential of [18F]FPEB
Time Frame: An average of 3 years
Secondary Outcomes
- distribution volume of [18F]FPEB(An average of 3 years)